The biotechnology company has entered a contract with the United States Army to develop custom recombinant spider silk for protective textile applications.
Kraig Biocraft Laboratories announced on Oct. 30, 2017 that it has entered a contract with the United States Army to develop custom recombinant spider silk. The genetically-engineered silkworm strains will be used for protective textile applications, and are required to fill a set of undisclosed performance objectives set by the army.
The silk polymers will be scaled up to produce upwards of 100 kgs of silk thread, and will be designed to generate higher tensile strength than the company’s comparable dragon silk fibers.
“This project is an excellent opportunity for us to demonstrate the incredible potential and power of engineered silk,” said Jon Rice, COO of Kraig Biocraft, in a company press release. “Tailoring the focus of our design efforts directly to a material’s performance requirements is a perfect example of the amazing flexibility, and possibilities, of engineered proteins. These new transgenics will be the beginning of our enhanced tactical fiber line of materials. While a monumental moment for the company, it is but one of many new and exciting opportunities for, spider silk, the company, and our shareholders.”
According to the company, additional research and production staff will be hired for the project, with in-house lab capabilities being developed at its Michigan-based research and production center, which opened in October 2017.
Source: Kraig Biocraft Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.